Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®
Valneva reported positive long-term antibody persistence data for its chikungunya vaccine IXCHIQ®, with 94% of participants maintaining neutralizing antibody levels five years after a single dose. The persistence was comparable across age groups (18-64 years and 65+ years), supporting the vaccine's differentiated profile for a disease with unpredictable epidemic outbreaks. The company continues to generate real-world evidence through post-commercialization studies, including a pilot vaccination campaign in Brazil that vaccinated approximately 80,000 adults.